MedTrace Logo

Acute Agitation in Emergency Psychiatry

NCT06752616 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2025-01-01

No results posted yet for this study

Summary

The purpose of the study is to improve the pharmacological treatment of psychiatric patients with acute agitation.

Conditions

  • Agitation

Interventions

DRUG

Sublingual Dexmedetomidine

Sublingual dexmedetomidine 180 mcg, possible second dose 90 mcg after 2 hrs

DRUG

Buccal midazolam

Buccal midazolam 10 mg, possible second dose 10 mg after 2 hrs

DRUG

Oral lorazepam

Oral lorazepam 4 mg, possible second dose 4 mg after 2 hrs

Sponsors & Collaborators

  • Copenhagen University Hospital - Bispebjerg and Frederiksberg Hospital

    collaborator UNKNOWN

  • Capital Region's Pharmacy (Region Hovedstadens Apotek), Marielundvej 25, 2730 Herlev, Denmark

    collaborator UNKNOWN

  • Lone Baandrup

    lead OTHER

Principal Investigators

  • Lone Baandrup, MD, DMSc · Mental Health Center Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-30
Primary Completion
2027-12-31
Completion
2027-12-31
FDA Drug
Yes

Countries

  • Denmark

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06752616 on ClinicalTrials.gov